Med
Overview
Med is a scientific journal, published by Cell Press since 2020 in English. The journal's country of origin is United States and its primary focus area is general medicine.
Details
Details
Abbr.
Med
Publisher
Cell Press
Start
2020
End
Continuing
Frequency
Monthly
p-ISSN
2666-6359
e-ISSN
2666-6340
Country
United States
Language
English
Specialty
General Medicine
Metrics
Metrics
h-index / Ranks: 9569
35
SJR / Ranks: 522
3253
CiteScore / Ranks: 804
13.00
Recent Articles
1.
Orlando A, Macaluso F
Med
. 2025 Mar;
6(3):100605.
PMID: 40088885
The QUASAR clinical development program evaluated the efficacy of guselkumab-an IL-23p19 subunit inhibitor-for the treatment of moderate-to-severe ulcerative colitis. Guselkumab demonstrated rapid control of symptoms, as well as significant rates...
2.
DAlessio A, Rimassa L
Med
. 2025 Mar;
6(3):100635.
PMID: 40088884
Transarterial chemoembolization (TACE) has long been the standard for intermediate-stage hepatocellular carcinoma (HCC), but two recent phase 3 trials have redefined treatment paradigms. The EMERALD-1 and LEAP-012 trials demonstrated significant...
3.
Randrian V, Rousseau B
Med
. 2025 Mar;
6(3):100636.
PMID: 40088883
Immunotherapy is highly efficient for the treatment of mismatch-repair-deficient metastatic colorectal cancer. Two recent articles challenge the current paradigm of anti-PD-1 monotherapy for the frontline treatment of metastatic mismatch-repair-deficient colorectal...
4.
Almassalha L, MacQuarrie K
Med
. 2025 Mar;
6(3):100610.
PMID: 40088882
Physician-scientists are a small proportion of the physician workforce. As early-career near-peer physician-scientists, we find value in the intersection of our expertise. This "percolation" overcomes both systemic and individual barriers....
5.
Pazo-Cid R, Pons P
Med
. 2025 Mar;
6(3):100543.
PMID: 40088881
Long et al. evaluated neoadjuvant (NAT) cadonilimab plus FLOT chemotherapy (ChT) in locally advanced gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma, showing a pathological complete response (pCR) rate of 21.1%...
6.
Percy A, Ryther R, Marsh E, Neul J, Benke T, Berry-Kravis E, et al.
Med
. 2025 Mar;
:100608.
PMID: 40043705
Background: Trofinetide is the first available treatment for Rett syndrome (RTT) and is approved in the United States in adults and pediatric patients aged ≥2 years. The DAFFODIL study was...
7.
Kennedy J, Vargas S, Fishman M, Alesi N, Baek S, Khabibillin D, et al.
Med
. 2025 Feb;
:100607.
PMID: 40020677
Background: Childhood interstitial and diffuse lung diseases are a collection of rare disorders with significant associated morbidity. Only a small subset of these diseases have precise diagnostic or therapeutic options...
8.
Murphy Z, Bianchini E, Smith A, Korner L, Russell T, Reinecke D, et al.
Med
. 2025 Feb;
:100604.
PMID: 40010345
Background: The diagnosis and treatment of tumors often depend on molecular-genetic data. However, rapid and iterative access to molecular data is not currently feasible during surgery, complicating intraoperative diagnosis and...
9.
Cappello M, Celsa C
Med
. 2025 Feb;
6(2):100572.
PMID: 39954670
The VIVID-1 study is a phase 3 randomized controlled trial assessing the efficacy and safety of mirikizumab in moderate-to-severe active Crohn's disease. The study confirms the advantage of selective IL-23...
10.
Hellenkamp K, Sato R, von Haehling S
Med
. 2025 Feb;
6(2):100570.
PMID: 39954669
The SUMMIT trial showed that the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist tirzepatide improves quality of life and reduces worsening heart failure (HF) events in patients with...